1 Prevalence and determinants of chronic respiratory diseases in adults in

2 Khartoum State, Sudan

- 3
- 4 Rana Ahmed¹, Nada Osman^{1,2}, Bandar Noory¹, Rashid Osman¹, Hana
- 5 ElHassan¹, Hind Eltigani¹, Rebecca Nightingale³, Andre FS Amaral⁴, Jaymini
- 6 Patel⁴, Peter G. Burney⁴, Kevin Mortimer^{5,6} Asma ElSony^{1,7}
- 7
- ⁸ ¹The Epidemiological Laboratory, Khartoum, Sudan
- 9 ²Federal Ministry of Health, Sudan
- ¹⁰ ³Liverpool School of Tropical Medicine, Liverpool, UK
- ¹¹ ⁴National Heart and Lung Institute, Imperial College, London, UK
- ¹² ⁵Liverpool University Hospitals NHS foundation Trust, Liverpool, UK
- ⁶University of Cambridge, Cambridge, UK
- ¹⁴ ⁷Global Alliance for Respiratory Diseases, Africa Representative
- 15
- 16 Running head: Chronic Respiratory Disease in adults, Sudan
- 17 Word count of the summary: 198
- 18 Word count of the text: 2909
- 19 Number of references: 35
- 20 Number of tables: 3
- 21 Number of figures: 2
- 22
- 23 Correspondence and requests for reprints: Asma El Sony
- 24 Director, Head of Scientific Activities at the Epidemiological Laboratory, a
- 25 WHO/EMRO Collaborating Centre for TB and Lung Diseases, PO Box 10012,
- 26 Khartoum,
- 27 Phone/Fax: +24 91 5515 2445
- 28 E-mail: asmaelsony@gmail.com
- 29
- 30

31 SUMMARY

32 Background

Chronic respiratory diseases are considered a significant cause of morbidity
 and mortality worldwide, although data from Africa are limited. This study
 aimed to determine the prevalence and determinants of chronic respiratory
 diseases in Khartoum, Sudan.

37 Methods

Data was collected from 516 participants, aged \ge 40, who had completed a questionnaire and undertook pre- and post-bronchodilator spirometry testing. Trained field workers conducted questionnaires and spirometry. Surveyweighted prevalence of respiratory symptoms and spirometric abnormalities were estimated. Regression analysis models were used to identify risk factors for chronic lung diseases.

44 Results

Using the NHANESIII reference equations, the prevalence of Chronic Airflow Obstruction (CAO) was 10%. The main risk factor was older age 60-69 years (Odds ratio 3.16, 95% Confidence Interval 1.20 – 8.31). Lower education, high body mass index and a history of tuberculosis were also identified as significant risk factors. The prevalence of a low forced vital capacity (FVC) using NHANES III was 62.7% [SE 2.2] and 11.3% [SE 1.4] using locally derived values.

52 **Conclusion**

53 The prevalence of spirometric abnormality mainly (low FVC); was high 54 suggesting that chronic respiratory disease is of substantial public health 55 importance in urban Sudan. Strategies for the prevention and control of these 56 problems are needed.

57

58 Keywords: COPD, CAO, Risk factors, low FVC, SSA

59

61

The Global Burden of Disease Study estimates 3.9 million deaths annually from chronic non-communicable respiratory diseases – mainly chronic obstructive pulmonary disease (COPD) and asthma^{1,2}. It's burden of deaths and morbidity is expected to increase over future decades especially in lowincome and middle-income countries (LMICs)^{3,4}.

67 Prevalence estimates for COPD in sub-Saharan Africa (SSA)^{5,6} are based on 68 limited epidemiological data which lack a standardized definition of COPD. A 69 recent systematic review reported a population prevalence of COPD in SSA 70 ranging from 1.7% to 24.8%⁷.

The prevalence and determinants of low FVC in SSA are barely understood however, its reported that Africans have reduced FVC compared with the Caucasian⁸. Moreover, studies reported an association between lung restriction and mortality and a higher prevalence of Chronic Respiratory Disease (CRD) in SSA that linked to numerous risk factors including early childhood exposures, poverty, biomass fuel exposure, smoking and pulmonary tuberculosis (TB) ⁹.

78

The Burden of Obstructive Lung Disease (BOLD) Initiative developed standardized methods for estimating the burden and determinants of chronic airflow obstruction (CAO) in populations aged 40 years and older^{10,11}. We did a BOLD study in Khartoum, Sudan to help fill the knowledge gap about the chronic respiratory diseases in Africa.

- 84
- 85

86 **METHODS**

87 Setting

Sudan's capital, Khartoum, is made up of 7 localities, across which there is a
mix of urban, semi-urban, rural, and internally displaced populations.

90

91 Sampling

Three localities, with a total population of 661,617, were randomly selected for sampling in this study and divided into clusters. Then 280, 258 and 158 households were randomly selected from Jabelawlya, Shargalneel and Omdurman localities respectively.

96

97 Participants

98 Using the BOLD protocol¹¹, we approached 998 participants from which $600 \ge$ 99 40 years old were included using a 3-stage stratified cluster sampling plan. 100 Potential participants who were institutionalized or medically unfit to perform 101 spirometry were excluded.

102

103 Data collection and management

104 All study participants completed a structured interview in the local Arabic 105 administered by trained interviewers. language Anthropometric 106 measurements along with pre-bronchodilator and post-bronchodilator 107 spirometry data were collected following the American Thoracic Society (ATS) 108 guidelines using the Easy One system (ndd Medizintechnik, Zurich, Switzerland) by three trained certified technicians¹¹. A minimal data or refusal 109 110 questionnaire was filled out for those not willing to participate in the full study. 111 The clinical data obtained included height, weight, pulse rate and waist and 112 hip circumference. Quality control was carried out at the BOLD coordinating 113 centre. Usable spirometry was defined as two or more acceptable blows, with 114 FEV₁ and FVC repeatability within 200 mL. Acceptable manoeuvres were 115 defined as those with a rapid start (back-extrapolated volume, 150 mL or 5% 116 of the FVC), lack of cough during the first second, and a small end-of-test 117 volume (<40 mL during the final second). The calibration of all spirometers

118 was verified to be accurate within 3.0% using a 3.00 L syringe at the 119 beginning of each day of testing. Spirometry traces were then classified 120 according to $FEV_1/FVC <$ lower limit of normality (LLN).

121 CAO was defined by post-bronchodilator (BD) FEV₁/FVC < LLN. Predicted 122 values based on standardized values for age, sex, and height were calculated 123 based on the Third National Health and Nutrition Examination Survey 1988-1994 (NHANES III) of white Americans¹². Local values were derived from 124 125 spirometry of non-smoking Sudanese adults with no respiratory symptoms or 126 diagnoses participating in this survey. CAO stages were categorised as: stage 127 1 or higher CAO (Post-BD FEV₁/FVC < LLN) and stage 2 or higher CAO 128 (Post-BD FEV₁/FVC < LLN and post-BD FEV₁ < 80% predicted).

129

130 Statistical analysis

Evaluation of selection bias and a comparison between groups was conducted using a chi-square test between participants who completed full data and minimal questionnaires with acceptable or unacceptable spirometry readings. Prevalence estimates of spirometric abnormalities stratified by age and sex were reported using the NHANES III ¹¹. Prevalence estimates using locally derived spirometry were also reported.

Univariable and multivariable logistic regression analyses were used to test associations between spirometry abnormalities and several exposure variables, including age, sex, education level, self-reported history of tuberculosis (TB), hypertension, diabetes, heart disease, body mass index, smoking status, smoking pack-years, exposure to indoor smoke from biomass fuel and occupational exposure.

A wealth score was developed based on the Mokken scale, to differentiate
between different levels of wealth using a count of owned assets^{13,14}.

Multivariable logistic regression models that included sex, age and all variables from the univariable analysis with a *p*-value <0.2 were then developed. The prevalence of respiratory symptoms was reported and associations with the study variables were tested using regression analysis. A description of the associations between abnormal spirometry and respiratory

symptoms was reported. The data were analysed using Stata IC 14
(StataCorp, College Station, TX). Prevalence estimates and regression
models were developed using survey weighting with the Svy package in Stata
(14).

154

155 Ethical considerations

Written informed consent was collected from study participants before data
collection. Ethical approval was obtained from the Imperial College London
and Khartoum state Ministry of Health.

159

160 **RESULTS**

The flow of participants through the study is shown in Figure 1. Of the 998 participants approached, 516 provided full questionnaire data and had BOLD centre-approved spirometry results. Eleven of the 998 participants declined to participate fully in the study but completed the minimal data questionnaire. The final response rate was 85.5% (n=696).

166

167 Participant characteristics

These are presented in Table 1. The mean age was 53.8 years (SD 10.4) and 59.3% were men. Overall, 35% completed primary school. Men had a higher level of education, as did the group aged 40-49 years when compared to other age groups. The mean number of household members was 7.8 (SD3.56) and the mean wealth score was 5.2 (SD 2.7).

173 Among respondents, 24% had smoked cigarettes while 50% of men were 174 current smokers. About 24% of smokers had more than a 20 pack-years of 175 exposure. Exposure to indoor biomass fuel for ≥ 6 months was reported by 176 82% of participants. In total, 78% reported having used an indoor open fire 177 fuelled by coal or charcoal for cooking for \geq 6 months, while 35% used 178 firewood and 21% used kerosene. Overall, women had a higher mean 179 number of hours of exposure to indoor biomass fuel per year than men (70% 180 vs. 54%). Farming was the most reported occupation (in 24%, Table 1).

181 In total, 23% of participants were obese and 7% were underweight.

182 Hypertension was self-reported by 20% of all participants, of whom 55% were

183 women. Diabetes was reported by 9% (9.5% of women and 8.8% of men).

184

185 Respiratory symptoms

186 At least one respiratory symptom was reported by 23% (Standard error (SE) 187 1.9) of participants; respiratory symptoms interfering with daily activities were 188 reported by 1.9% (SE 0.5). Cough was reported by 10.4% (SE 1.3), with the 189 highest prevalence recorded in participants aged 70+ years (11.9% [SE 4.9]). 190 Chronic cough (lasting for more than 3 months per year) was reported by 191 4.0% (SE 0.8). Production of sputum was reported by 11% (SE 1.3) and 192 chronic production of sputum (for more than 3 months per year) was reported 193 by 5% (SE 0.09). Shortness of breath was reported by 11% (SE 1.3) and 41% 194 (SE 6.5) of this group reported that breathing problems made it difficult to walk 195 more than 100 yards. Wheeze in the past 12 months in the absence of cold 196 was the least commonly reported symptom (3.0% [SE 0.7], Supplementary 197 Table S1).

198

199 Spirometry

No statistically significant differences were found between the groups who did
or did not complete the spirometry test. Using NHANES III, stage 1 or higher
CAO prevalence was 10.3% [SE 1.4] (9.2 [SE 1.7] of men and 11.2 [SE 2.4]
of women). Using the locally derived reference range the prevalence was
5.7% [SE 1.1] (5.2% [SE 1.3] of men and 6.2 [SE 1.9] of women).

205 Participants aged 60-69 years had the highest prevalence of stage 1 or higher 206 CAO (13.4% [SE 3.8]). Prevalence of stage 2 or higher CAO was 9.4% [SE 207 1.4] (8.8% [SE 1.7] of men and 10.1% [SE 2.2] of women). Using the locally 208 derived reference range, 3.0% [SE 0.8] of the study population had stage 2 or 209 higher CAO (2.9% [SE 0.9] of men and 3.1% [SE 1.3] of women). Similarly, 210 participants aged 60-69 years had the highest prevalence of stage 2 or higher 211 CAO using both the local and NHANES reference ranges (17.6% [SE 4.2] vs. 212 6.7% [SE 2.6]).

Low FVC was seen in 62.7% [SE 2.2] (65.2% [SE 2.8] in men vs. 59.8% [SE
3.5] in women). Cough was less reported in those with low FVC (OR 0.48,
95% CI 0.27 - 0.87).

Airflow reversibility was found in 6.1% [SE 1.1] of the total study population and was more common in women than men (8% [SE 1.9] vs. 4.4% [SE 1.1]). Airflow obstruction persisted after use of a bronchodilator in 8.4% (SE 4.7) of participants with reversibility. (Supplementary Table S2, Figure 2).

220

221 Factors associated with respiratory symptoms

222 In both univariable and multivariable analyses, chronic production of sputum 223 was negatively associated with age (Supplementary Tables S3 and S4). 224 Participants aged 60-69 years were less likely to report chronic sputum 225 production (OR 0.39, 95% CI 0.16 - 0.93) than those aged 40-49 years. There 226 was a significantly increased likelihood of regular sputum production with 227 being an ex-smoker (OR 2.66, 95% CI 1.09 - 6.50) and having diabetes (OR 228 4.04, 95% CI 1.82 - 8.96). Participants with lower socioeconomic status; who 229 have a wealth score of 2 tend to have higher odds of sputum production 230 compared to those with zero score (OR 7.18, 95% CI 1.16 - 44.53).

In multivariable analysis, the likelihood of having shortness of breath was significantly greater in participants exposed to indoor biomass fuel (OR 4.56, 95% CI 1.44 - 14.43). The presence of wheeze was only associated with being a current smoker (OR 3.49, 95% CI 1.02 - 11.96). There were no significant associations between CAO and respiratory symptoms.

236

237 Factors associated with post-bronchodilator airway obstruction

Participants aged 60-69 years had the highest risks of CAO stage 1 or higher
(OR 3.16, 95% Cl 1.20 - 8.31) and stage 2 or higher (OR 3.39, 95% Cl 1.04 6.93) than those aged 40-49 years. In contrast, having higher education level
was protective against any obstruction in bivariate analysis (OR 0.31, 95% Cl
0.13 - 0.76), however no association was identified after adjustment. Similarly,
being overweight or obese was protective against any obstruction (OR 0.38,

244 95% CI 0.17 - 0.82 and OR 0.34, 95% CI 0.13 - 0.99, respectively). Those 245 with a history of TB were less likely to have any obstruction (OR 0.08, 95% CI 246 0.01 - 0.59). There was no observed trend in Mokken scale points and CAO. 247 However, participants with a low socioeconomic position who scored >2 in 248 wealth score had the highest odds of developing stage 1 or higher and stage 249 2 or higher CAO (OR 6.00, 95% CI 1.03 - 34.94). No other factor was 250 significantly associated with airway obstruction (Table 2, Supplementary 251 Tables S5 and S6).

Using the local reference range, participants aged 60-69 years were more likely to have CAO stage 1 or higher than their younger counterparts (OR 3.10, 95% CI 1.01 - 9.57), and being obese were negatively associated with obstruction (OR 0.29, 95% CI 0.09 - 0.97) in multivariable analysis. A higher education level was protective against CAO in the bivariate analysis (OR 0.23, 95% CI 0.063 - 0.83) however no association was identified after adjustment.

258

259 Factors associated with low FVC

260 Using the NHANES III, low FVC was associated with smoking 10-20 packs 261 year history, having primary or higher-level education, having more people in 262 house and being obese (OR 2.79, 95% CI 1.11 - 7.00; OR 2.42, 95% CI 1.43 -263 4.09; OR 0.94, 95% CI 0.89 - 0.99 and OR 1.73, 95% CI 1.04 - 2.86 264 respectively) in bivariate analysis. In multivariate analysis, those aged 50-59 265 were less likely to have low FVC compared to those aged 40-49 years (OR 266 0.50, 95%CI 0.31 - 0.81). No other factors were associated with low FVC in 267 multivariate analysis (Table 3).

268

269 **DISCUSSION**

270

Discoulding

This population-based survey aimed to investigate the prevalence and determinants of chronic respiratory diseases in the population aged \geq 40 years in urban Sudan. Our main finding was that approximately 10% of people in this age group had CAO. CAO stage II or higher was detected in 9.4% of the overall population using the same reference range, though this decreased to 3.0% when the local reference range was used.

A higher prevalence of obstruction when using the NHANES III compared to the local reference range has been reported previously⁹. In spite of being the only available data, values of the local methodology might be more ethnically suitable compared to NHANES III. However, different exposures in this setting may constrain its use^{9,15}.

282 The determined prevalence of spirometric obstruction is consistent with that in 283 similar studies from sub-Saharan Africa, where the prevalence of smoking is high¹⁶. Previous BOLD studies reported COPD prevalence of 23% in men and 284 16.9% in women in South Africa¹⁷ and 7.7% in Nigeria^{7,18,19}. CAO prevalence 285 286 reported from a multinational BOLD study was 11.5% in men and 8.8% in 287 women which is consistent with our findings²⁰. Compared to studies from the MENA region (Middle East and North Africa), our findings are higher than 288 those in Saudi Arabia²¹, Tunisia^{22,23}, Morocco²⁴, Algeria²⁵ and Lebanon²⁶. 289

290 Older age was the main risk factor for CAO in our study, which is consistent with both regional and global findings^{7,9,16,18}. The absence of an association 291 292 with CAO and cigarette smoking might be due to that 50% of the smokers in 293 our study reported a smoking history of ≤10 pack-years. Countries with lower 294 smoking rates, such as Malawi and Rwanda, have a lower reported 295 prevalence of COPD^{9,27}. However, the age group 60-69 years who reported 296 the highest smoking rates in this study had the highest prevalence of 297 spirometric obstruction and higher prevalence of both chronic cough and 298 chronic phlegm. The high prevalence of CAO might be due to exposure to air 299 pollutants coming from the large number of factories and cars in the State.

A higher educational level was protective against CAO which is compatible with other studies^{10,18,28}. Conversely, a significant association between low socioeconomic status and developing CAO was found in this study, consistent with studies suggesting that low socioeconomic status may be associated with a progression of airflow limitation^{16,29}.

We did not observe any association between exposure to biomass fuel and obstruction. This is consistent with the study that included 25 BOLD sites which found that airflow obstruction measured by post-bronchodilator spirometry was not associated with use of solid fuels for cooking or heating³⁰,

and findings in other large studies in China^{31,32}. A recent review of studies on
COPD and household air pollution concluded that it was not possible to define
clear causal links between the two³³.

312 Shortness of breath, one of the most common symptoms of CAO, was 313 significantly higher in those who use biomass fuel for ≥ 6 months. It is 314 possible that this latter group suffer from chronic bronchitis or similar non-315 obstructive lung diseases. In addition, the finding that only 0.2% reported TB 316 might account for the significant negative association between TB and obstruction, which is in conflict with published literature³⁴. Identification of TB 317 318 was based on self-reporting and many factors might affect the validity of the 319 answers provided given that TB is a highly stigmatized clinical condition and the proportion reported here may be an underestimate³⁵. 320

A high prevalence of low FVC (62.7%) was identified in this study. BOLD studies in SSA and other studies in resource-poor settings reports similar findings ^{9,17}. That 55% of the study population was overweight might partly explain the high level of low FVC⁸.

325 To our knowledge, this is the first study to provide a detailed prevalence 326 estimates of CAO in Sudanese adults using internationally standardised 327 methods and procedures as well as an appropriate sampling technique. We 328 acknowledge our study had limitations. Missing information for a proportion of 329 the study participants limited the cluster-weighted analysis. Furthermore, 330 reasons for exclusion were not recorded, meaning those who were excluded 331 for medical reasons were not separated from those who were excluded for 332 other reasons. Having spirometry readings with no matching questionnaire 333 data for 54 participants and unacceptable spirometry readings from 79 334 participants decreased the sample size and study power.

In conclusion, this study found evidence that chronic respiratory disease is a major problem in Sudan and needs to be considered in future public health policies and research. The overall prevalence of CAO in urban Sudan is similar to that found by other BOLD studies in countries with similar smoking rates. However, it is relatively high when compared to other countries in sub-Saharan Africa and the MENA regions. A high prevalence of low FVC was

341 also identified, the aetiology and pathophysiology of which are unknown and 342 require further investigation. These findings suggest the need for 343 strengthening the chronic respiratory disease programs and provision of 344 improved diagnostic and treatment options for CRDs to address 345 underestimation and diagnosis.

346

347 ACKNOWLEDGEMENTS

This work was supported by Welcome Trust, UK - grant (085790/Z/08/Z) for the

- BOLD (Burden of Obstructive Lung Disease) study. Prof. Mortimer received
- 351 advisory board fees from AstraZeneca outside this work and Dr Nightingale
- reports grants from Medical Research Council, outside the submitted work.
- We thank the teams of data collectors and spirometry technicians from Sudan for their hard work during the household survey. We also thank the members of the BOLD Coordinating Centre at the Imperial College London for its assistance with spirometry training, quality control, and data management in the study.

358

359 CONTRIBUTION STATEMENT

- 360 Dr Rana Ahmed wrote the first draft of manuscript, conducted data cleaning,
- 361 verification, interpretation and analysis of this study.
- 362 Dr Nada Osman lead the study and contributed to manuscript writing and363 revision.
- 364 Dr Bandar Noory coordinated the study, supervised the data collection and 365 contributed to manuscript writing and revision.
- 366 Dr Rashid Osman revised the spirometry readings, contributed to the writing367 and revision.
- 368 Ms Hind Eltigani contributed to data collection, data verification and 369 participated in writing.

Ms Hana ElHassan was responsible for the field administration of the overall project. She contributed to the writing and revision. Dr Rebecca Nightingale contributed to the writing and analysis of this manuscript. Dr Andre FS Amaral reviewed and contributed to the writing of this manuscript. Mrs. Jaymini Patel provided the clean data, analysis report and revised the manuscript. Prof. Burney reviewed and contributed to the methodology of the study and reviewed the writing of this manuscript. Prof. Kevin Mortimer supervised, reviewed and contributed to the writing of this manuscript. Prof. Asma El Sony was the principal investigator of the study, she supervised, reviewed and contributed to the writing of this manuscript.

398

399

400 **REFERENCES**

- Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*.
 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
- Global Burden of Disease Collaborative Network.Global Burden of
 Disease Study 2019 (GBD 2019) Results. Seattle, United States:
 Institute for Health Metrics and Evaluation (IHME), 2020. Global Health
 Data Exchange. http://ghdx.healthdata.org/gbd-results-tool. Published
 2019.
- 410 3. de-Graft Aikins A, Unwin N, Agyemang C, Allotey P, Campbell C,
 411 Arhinful D. Tackling Africa's chronic disease burden: from the local to
 412 the global. *Global Health*. 2010;6(August 2016):5. doi:10.1186/1744413 8603-6-5
- 414 4. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low415 income and middle-income countries: from challenges to solutions.
 416 *Lancet.* 2021;397(10277):928-940. doi:10.1016/S0140-6736(21)00458417 X
- 418 5. Salvi S. The silent epidemic of COPD in Africa. *Lancet Glob Heal*.
 419 2015;3(1):e6-e7. doi:10.1016/S2214-109X(14)70359-6
- 420 6. Mannino DM. COPD in Africa: the coming storm. *Int J Tuberc Lung Dis*.
 421 2013;17(5):572. doi:10.5588/ijtld.13.0157
- Awokola BI, Amusa GA, Jewell CP, et al. Chronic obstructive pulmonary
 disease in sub-Saharan Africa. *Int J Tuberc Lung Dis.* 2022;26(3):232242. doi:10.5588/ijtld.21.0394
- B. Obaseki DO, Erhabor GE, Awopeju OF, et al. Reduced forced vital
 capacity in an African population prevalence and risk factors. *Ann Am Thorac Soc.* 2017;14(5):714-721. doi:10.1513/AnnalsATS.201608 598OC

| 429 | 9. | Meghji J, Nadeau G, Davis KJ, et al. Noncommunicable lung disease in |
|-----|----|--|
| 430 | | sub-Saharan Africa a community-based cross-sectional study of adults |
| 431 | | in urban Malawi. Am J Respir Crit Care Med. 2016;194(1). |
| 432 | | doi:10.1164/rccm.201509-1807OC |

- 433 10. Buist a. S, Vollmer WM, McBurnie M a. Worldwide burden of COPD in
 434 high- and low-income countries. Part I. The burden of obstructive lung
 435 disease (BOLD) initiative. *Int J Tuberc Lung Dis.* 2008;12(7):703-708.
 436 doi:S0140-6736(07)61377-4 [pii] 10.1016/S0140-6736(07)61377-4 [doi]
- 437 11. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive
 438 Lung Disease Initiative (BOLD): rationale and design. *COPD*.
 439 2005;2(2):277-283. doi:10.1081/COPD-200057610
- Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values
 from a sample of the general U.S. Population. *Am J Respir Crit Care Med.* 1999;159(1):179-187. doi:10.1164/ajrccm.159.1.9712108
- Townend J, Minelli C, Harrabi I, et al. Development of an international
 scale of socio-economic position based on household assets. *Emerg Themes Epidemiol.* 2015;12(1):1-11. doi:10.1186/s12982-015-0035-6
- 446 14. Townend J, Minelli C, Mortimer K, et al. The association between
 447 chronic airflow obstruction and poverty in 12 sites of the multinational
 448 BOLD study. *Eur Respir J*. 2017;49(6).
- 449 15. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values
 450 for spirometry for the 3-95-yr age range: The global lung function 2012
 451 equations. *Eur Respir J.* 2012;40(6):1324-1343.
 452 doi:10.1183/09031936.00080312
- Adeloye D, Basquill C, Papana A, Chan KY, Rudan I, Campbell H. An
 Estimate of the Prevalence of COPD in Africa: A Systematic Analysis. *COPD J Chronic Obstr Pulm Dis.* 2015;12(1):71-81.
 doi:10.3109/15412555.2014.908834
- 457 17. Burney P, Jithoo A, Kato B, et al. Chronic obstructive pulmonary
 458 disease mortality and prevalence: the associations with smoking and
 459 poverty—a BOLD analysis. *Thorax.* 2014;69(5):465-473.

460 doi:10.1136/thoraxjnl-2013-204460

- 461 18. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the
 462 prevalence of COPD (The BOLD Study): a population-based prevalence
 463 study. *Lancet*. 2007;370(9589):741-750. doi:10.1016/S0140464 6736(07)61377-4
- 465 19. Obaseki DO, Erhabor GE, Gnatiuc L, Adewole OO, Buist SA, Burney
 466 PG. Chronic Airflow Obstruction in a Black African Population: Results
 467 of BOLD Study, Ile-Ife, Nigeria. COPD J Chronic Obstr Pulm Dis.
 468 2016;13(1):42-49. doi:10.3109/15412555.2015.1041102
- 469 Burney P, Patel J, Minelli C, et al. Prevalence and Population 20. 470 Attributable Risk for Chronic Airflow Obstruction in a Large Multinational 471 Crit Care Med. November 2020. Study. Am J Respir 472 doi:10.1164/rccm.202005-1990OC
- Al Ghobain M, Alhamad EH, Alorainy HS, Al Kassimi F, Lababidi H, AlHajjaj MS. The prevalence of chronic obstructive pulmonary disease in
 Riyadh, Saudi Arabia: a BOLD study. *Int J Tuberc Lung Dis.*2015;19(10):1252-1257. doi:10.5588/ijtld.14.0939
- 477 22. Daldoul H, Denguezli M, Jithoo A, et al. Prevalence of COPD and
 478 tobacco smoking in Tunisia Results from the BOLD study. Int J
 479 Environ Res Public Health. 2013;10(12):7257-7271.
 480 doi:10.3390/ijerph10127257
- 23. Denguezli M, Daldoul H, Harrabi I, et al. COPD in Nonsmokers: Reports
 from the Tunisian Population-Based Burden of Obstructive Lung
 Disease Study. *PLoS One.* 2016;11(3):e0151981.
 doi:10.1371/journal.pone.0151981
- 485 24. El Rhazi K, Nejjari C, BenJelloun MC, El Biaze M, Attassi M, Garcia486 Larsen V. Prevalence of chronic obstructive pulmonary disease in Fez,
 487 Morocco: results from the BOLD study. *Int J Tuberc Lung Dis.*488 2016;20(1):136-141. doi:10.5588/ijtld.15.0029
- 489 25. Hacene Cherkaski H, Khalloufi F, Atoui F, et al. The prevalence of
 490 COPD in Annaba, Algeria: Results of the BOLD study. *Eur Respir J*.

491 2014;44(Suppl 58).

492 26. Ben Abdallah FC, Taktak S, Chtourou A, Mahouachi R, Kheder A Ben.
493 Burden of Chronic Respiratory Diseases (CRD) in Middle East and
494 North Africa (MENA). *World Allergy Organ J.* 2011;4(1 Suppl):S6-8.
495 doi:10.1097/WOX.0b013e3182093cbb

- 496 27. Musafiri S, Joos G, Van Meerbeeck JP. Asthma, atopy and COPD in
 497 sub-Saharan countries: the challenges. *East Afr J Public Health*.
 498 2011;8(2):161-163.
- 499 28. Mannino DM, Buist AS. Global burden of COPD: risk factors,
 500 prevalence, and future trends. *Lancet.* 2007;370(9589):765-773.
 501 doi:10.1016/S0140-6736(07)61380-4
- Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never
 smokers: Results from the population-based burden of obstructive lung
 disease study. *Chest.* 2011;139(4):752-763. doi:10.1378/chest.10-1253
- 30. André FSA, Jaymini P, Bernet SK, Al E. Airflow obstruction and use of
 solid fuels for cooking or heating: BOLD results. *Am J Respir Crit Care Med.* 2017;182(6):745-751. doi:10.1164/rccm.201003-0326OC
- 508 Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic 31. 509 obstructive pulmonary disease in China (the China Pulmonary Health 510 [CPH] study): а national cross-sectional study. Lancet. 511 2018;391(10131):1706-1717. doi:https://doi.org/10.1016/S0140-512 6736(18)30841-9
- 513 32. Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in
 514 China: a nationwide prevalence study. *Lancet Respir Med.*515 2018;6(6):421-430. doi:https://doi.org/10.1016/S2213-2600(18)30103-6
- 33. Mortimer K, de Oca MM, Salvi S, et al. Household air pollution and
 COPD: cause and effect or confounding by other aspects of poverty? *Int J Tuberc Lung Dis.* 2022;26(3):206. doi:10.5588/ijtld.21.0570
- 34. Osman RK, Mortimer K, Bjune G, Sony AI EI. Chronic respiratory
 disease in adults treated for tuberculosis in Khartoum, Sudan. *Public Heal Action.* 2016;I(3):199-204.

- 522 35. Ziyada MM. Exploring tuberculosis Related Stigma in Khartoum-
- 523 Sudan :: A qualitative study. 2010;(September).
- 524 doi:10.13140/RG.2.1.4193.8804

525

- 526
- 527

528 Table 1 Characteristics of all subjects who completed a full BOLD core

529

questionnaire, including those with and without spirometry results

| Variable (n) | n (%) | | | |
|--|------------|--|--|--|
| Age group, years (n=595) | | | | |
| 40-49 | 226 (38.0) | | | |
| 50–59 | 200 (33.6) | | | |
| 60–69 | 108 (18.2) | | | |
| 70+ | 61 (10.3) | | | |
| Sex (n=595) | | | | |
| Male | 353 (59.3) | | | |
| Female | 242 (40.7) | | | |
| Level of education (n=593) | | | | |
| None | 125 (21.1) | | | |
| Primary school | 207 (34.9) | | | |
| Middle school | 69 (11.6) | | | |
| High school or above | 192 (32.4) | | | |
| Mean years of education (n=595) | 6.49 (5.5) | | | |
| Smoking status (n=595) | | | | |
| Current smoker | 55 (9.2) | | | |
| Ex-smoker | 86 (14.5) | | | |
| Never smoked | 454 (76.3) | | | |
| Pack-years of smoking (n=595) | | | | |
| Never smoked | 454 (76.3) | | | |
| 0 -10 | 71 (11.9) | | | |
| 10-20 | 36(6.1) | | | |
| ≥20 | 34(5.7) | | | |
| Biomass exposure (n=532) | | | | |
| Yes | 422 (82.4) | | | |
| No | 90 (17.6) | | | |
| Farm work for ≥3 months (n=527) | | | | |
| Yes | 126 (23.9) | | | |
| No | 401 (76.1) | | | |
| Body mass index (n=588) | | | | |
| Underweight (<18.5) | 39 (6.6) | | | |
| Normal (18.5–24.9) | 226 (38.4) | | | |
| Overweight (25.0–29.9) | 189 (32.1) | | | |
| Obese (≥30) | 134 (22.8) | | | |
| Reported history of tuberculosis (n=595) | | | | |
| Yes | 5 (0.8) | | | |

| No | 590 (99.2) | |
|---|------------|--|
| Reported history of hypertension (n=595) | | |
| Yes | 118 (19.8) | |
| No | 477 (80.2) | |
| Reported history of diabetes (n=595) | | |
| Yes | 54 (9.1) | |
| No | 541 (90.9) | |
| Reported history of heart disease (n=595) | | |
| Yes | 12 (2.0) | |
| No | 583 (98.0) | |

- 531 **Table 2** Multivariable associations of risk factors with stage 1 or higher CAO
- 532 defined using NHANES III (Post-BD FEV₁/FVC < LLN; n=53/516) and Stage 2
- 533 or higher CAO defined using NHANES III (Post-BD FEV1/FVC < LLN and
- 534 post-BD FEV₁ < 80% predicted; n=49/516)

| Variable | Multivariable association | | Multivariable association | | | |
|----------------------------|---------------------------|-------------|---------------------------|-------------|--|--|
| | with CAO stage 1 or | | with CAO stage 2 or | | | |
| | higher | | higher | | | |
| | OR | 95% CI | OR | 95% CI | | |
| Age group, years | | | | | | |
| 40–49 | 1.0 | - | 1.0 | - | | |
| 50–59 | 2.13 | 0.84 - 5.41 | 1.86 | 0.73 - 4.77 | | |
| 60–69 | 3.16 * | 1.20 - 8.32 | 2.78* | 1.07 - 7.26 | | |
| 70+ | 1.91 | 0.60 - 6.10 | 0.91 | 0.21 - 3.92 | | |
| Sex | | | | | | |
| Male | 1.0 | - | 1.0 | - | | |
| Female | 1.31 | 0.61 - 2.84 | 1.67 | 0.76 - 3.66 | | |
| Level of education | | | | | | |
| None | 1.0 | - | 1.0 | - | | |
| Primary school | 0.61 | 0.27 - 1.34 | 0.62 | 0.27 - 1.44 | | |
| Middle school | 1.23 | 0.40 - 3.81 | 1.03 | 0.32 - 3.36 | | |
| High school or above | 0.71 | 0.28 - 1.78 | 0.69 | 0.26 - 1.86 | | |
| Body mass index | | | | | | |
| Underweight (<18.5) | 1.87 | 0.66 - 5.30 | 1.16 | 0.33 - 4.07 | | |
| Normal (18.5–24.9) | 1.0 | - | - | | | |
| Overweight (25.0–29.9) | 0.43 | 0.18 - 1.01 | 0.37* | 0.15 - 0.92 | | |
| Obese (≥30) | 0.35 | 0.11 - 1.17 | 0.29* | 0.08 - 1.07 | | |
| Self-reported TB | | | | | | |
| No | 1.0 | - | 1.0 | 0 | | |
| Yes | 0.08* | 0.01 - 0.59 | 0.07* | 0.01 - 0.48 | | |
| Number of people living in | ± | ± | 1.05 | 0.96 - 1.16 | | |
| Used firewood | | | | | | |
| No | ± | ± | 1.0 | - | | |
| Yes | ± | ± | 0.58 | 0.29 - 1.19 | | |
| Wealth score/Mokken scale | ± | ± | 0.96 | 0.83 - 1.11 | | |

- ⁵³⁵ **p* <0.05. CAO, Chronic Airflow Obstruction; CI, confidence interval; OR, odds ratio;
- 536 FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity ratio; LLN,
- 537 lower limit of normal, (±) not included in multivariable analysis

- **Table 3** Multivariable associations of risk factors with low FVC, defined using

542 NHANES III reference range (FVC < LLN), n= 315/516

| Variable | Multivariable association | | |
|---------------------------|---------------------------|-------------|--|
| | OR | 95% CI | |
| Age group | | | |
| 40-49 | 1 | - | |
| 50-59 | 0.50* | 0.31 - 0.81 | |
| 60-69 | 0.29* | 0.17 - 0.51 | |
| 70+ | 0.25* | 0.12 - 0.53 | |
| Sex | | | |
| Male | 1 | - | |
| Female | 0.78 | 0.48 - 1.24 | |
| Body Mass Index (kg/m2) | | | |
| Underweight (BMI<18.5) | 0.95 | 0.43 - 2.07 | |
| Normal (BMI 18-25) | 1 | - | |
| Overweight (BMI 25-30) | 1.39 | 0.85 - 2.27 | |
| Obese (BMI >30) | 1.55 | 0.87 - 2.80 | |
| Packs-year of smoking | | | |
| Never | 1 | - | |
| 0-10 | 1.09 | 0.59 - 2.02 | |
| 10-20 | 2.45 | 0.88 - 6.86 | |
| ≥20 | 1.00 | 0.47 - 2.11 | |
| Wealth score/Mokken scale | 0.97 | 0.90 -1.04 | |

**p* <0.05. CI, confidence interval; OR, odds ratio; FVC, forced vital capacity ratio;

LLN, lower limit of normal

- **Figure 1** Participant flow diagram

Figure 2 Estimated Population Prevalence of chronic airflow obstruction by age and sex using National Health and Nutrition Examination Survey reference ranges (NHANES) for the Sudanese population in participants completing standard American Thoracic Society spirometry (n=516). The upper graph represents the prevalence of Stage 1 or higher CAO (Post-BD FEV1/FVC < LLN) and the lower graph represents the prevalence of Stage 2 or higher CAO (Post-BD FEV1/FVC < LLN and post-BD FEV1 < 80% predicted).